Financial News

Nicox Enters Research Collaboration with Re-Vana Therapeutics on its Next Generation of Stand-alone NO-donors in a Novel Sustained Release Ophthalmic Formulation

Sophia Antipolis, France and Belfast, Northern Ireland
Nicox SA (Euronext Paris: FR0013018124, COX), the international ophthalmic company, and Re-Vana Therapeutics Ltd, ocular pharmaceutical and drug delivery company, today announced that they have entered into a research collaboration to explore combining Nicox’s next generation of stand-alone nitric oxide (NO)-donors with Re-Vana’s EyeLief™ long-acting photo-crosslinked biodegradable drug delivery platform for the reduction of intraocular pressure (IOP),

Read more

Nicox and pSivida Enter Strategic Collaboration Agreement to Develop Sustained Release Drug to Lower Intraocular Pressure in Patients with Glaucoma

Focus will be on Combining Nicox’s New Nitric Oxide Donating Compounds with pSivida’s Bioerodible Sustained Release Delivery Technology  
Sophia Antipolis, France and Watertown, Mass, United States
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic company, and pSivida Corp, (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today announced their entry into a collaboration agreement to explore the potential of combining Nicox’s nitric oxide (NO)-donating compounds with pSivida’s bioerodible sustained release drug delivery system,

Read more
More news